drugset / Trial / NCT02055066
A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This a first-in-human study of an antibody blocking the function of the oncogene c-met in patients with cancer.
Timeline
- Start
- 2014-01
- Primary completion
- 2017-03
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARGX 111 | Unknown | 0.3 mg/kg | — |
| Subject | ARGX 111 | Unknown | 1 mg/kg | — |
| Subject | ARGX 111 | Unknown | 3 mg/kg | — |
| Subject | ARGX 111 | Unknown | 10 mg/kg | — |